Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
There is a need for biomarkers that can rapidly and sensitively detect therapeutic benefits of therapies designed to "rehydrate" airways and monitor disease severity and progression. In this study the investigators will evaluate the stability of mucus concentration in patients with bronquiectasis (CF and NCBF) and its ability to respond to acute exacerbations in order to assess whether it can be a good candidate for biomarker.
Full description
Prospective cross-sectional study of repeated measurements. The recruitment will be performed in 3 different cities of Spain: Zaragoza, Barcelona and Murcia.
Subjects will be asked to repeatedly collect spontaneous and induced sputum samples in both stable and exacerbated conditions. All samples will be collected autonomously by patients in their homes after they have been instructed and supervised. Hypertonic saline nebulization will be used for sputum induction.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
36 participants in 1 patient group
Loading...
Central trial contact
Marta San Miguel Pagola, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal